Update: Intellect Neurosciences, Inc. (ILNS.OB) Print E-mail
By Staff and Wire Reports   
Tuesday, 13 July 2010 07:57

The article we promised to publish about Intellect Neurosciences, Inc. (ILNS.OB) has been delayed by a couple of hours by our legal department.

Because the story contains certain information that has never been disclosed to investors, some of the facts which will be unveiled for the first time must be double and triple checked for accuracy with various sources- especially because they involve publicly traded companies.

Readers can expect to see the story, in one form or another, later this morning here and via the various syndicates and news wires which carry our content.

Yesterday, Dr. Daniel Chain, CEO of ILNS and inventor of the technology platform behind the "most promising" drug development in Alzheimer's (see: yesterday's front page story) was interviewed on Southern California's KPCC by Patt Morrison.

The live two-hour public affairs show, known for its large audience and innovative discussions of local politics and culture, and for its presentation of national and world news, featured Dr. Chain and a representative from the Alzheimer's Association as that group convenes an International Conference (ICAD) to look at the latest research on diagnosing, treating and preventing the disease.


Click To See Program Info

Pat is an op-ed columnist and writer for the Los Angeles Times, author of a best-selling book, public television and radio host. For those who did not get our alert about it, the broadcast appears as a podcast at the link below:

Live Stream Link: http://www.scpr.org/programs/patt-morrison/2010/07/12/alzheimers-association-convenes-international-conf/




"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter